[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2012DN02081A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02081A
IN2012DN02081A IN2081DEN2012A IN2012DN02081A IN 2012DN02081 A IN2012DN02081 A IN 2012DN02081A IN 2081DEN2012 A IN2081DEN2012 A IN 2081DEN2012A IN 2012DN02081 A IN2012DN02081 A IN 2012DN02081A
Authority
IN
India
Prior art keywords
prophylaxis
disorders
preparation
treatment
heteroarylmethyl
Prior art date
Application number
Other languages
English (en)
Inventor
Lucking Ulrich
Cleve Arwed
Haendler Bernard
Faus Gimenez Hortensia
Kohr Silke
Irlbacher Horst
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of IN2012DN02081A publication Critical patent/IN2012DN02081A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN2081DEN2012 2009-09-11 2010-08-28 IN2012DN02081A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17
PCT/EP2010/005297 WO2011029537A1 (en) 2009-09-11 2010-08-28 Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs

Publications (1)

Publication Number Publication Date
IN2012DN02081A true IN2012DN02081A (pt) 2015-08-21

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2081DEN2012 IN2012DN02081A (pt) 2009-09-11 2010-08-28

Country Status (27)

Country Link
US (1) US20120251551A1 (pt)
EP (1) EP2475653A1 (pt)
JP (1) JP2013504523A (pt)
KR (1) KR20120065396A (pt)
CN (1) CN102639523A (pt)
AR (1) AR078166A1 (pt)
AU (1) AU2010294588A1 (pt)
BR (1) BR112012005526A2 (pt)
CA (1) CA2773591A1 (pt)
CL (1) CL2012000623A1 (pt)
CO (1) CO6511228A2 (pt)
CR (1) CR20120113A (pt)
CU (1) CU20120042A7 (pt)
DO (1) DOP2012000063A (pt)
EA (1) EA201200473A1 (pt)
EC (1) ECSP12011716A (pt)
IL (1) IL218390A0 (pt)
IN (1) IN2012DN02081A (pt)
MA (1) MA33566B1 (pt)
MX (1) MX2012002977A (pt)
NZ (1) NZ598643A (pt)
PE (1) PE20121180A1 (pt)
SG (1) SG178919A1 (pt)
TN (1) TN2012000108A1 (pt)
TW (1) TW201111378A (pt)
UY (1) UY32882A (pt)
WO (1) WO2011029537A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722660B2 (en) 2010-02-17 2014-05-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2011150457A2 (en) * 2010-06-01 2011-12-08 The University Of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
PL2794627T3 (pl) 2011-12-22 2019-04-30 Alios Biopharma Inc Podstawione nukleozydy, nukleotydy i ich analogi
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AP3545A (en) 2012-05-25 2016-01-14 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
SI2935303T1 (sl) 2012-12-21 2021-08-31 Janssen Biopharma, Inc. 4'-fluoro-nukleozidi, 4'-fluoro-nukleotidi in njihovi analogi za zdravljenje HCV
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
HRP20230086T1 (hr) * 2013-12-11 2023-03-31 Celgene Quanticel Research, Inc. Inhibitori lizin specifične demetilaze-1
EP3083596A1 (en) 2013-12-18 2016-10-26 Basf Se Azole compounds carrying an imine-derived substituent
US9682960B2 (en) * 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
CA2944103A1 (en) 2014-05-07 2015-11-12 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
WO2017060167A1 (en) 2015-10-08 2017-04-13 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CA3057892A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
JP2020520373A (ja) 2017-05-18 2020-07-09 ピーアイ インダストリーズ リミテッドPi Industries Ltd 植物病原性微生物に対して有用なホルムイミドアミジン化合物
SG11202006470RA (en) 2018-02-13 2020-08-28 Bayer Ag Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma
EP3953342A4 (en) * 2019-04-11 2023-01-11 University of Miami IMPROVED NOTCH TRANSCRIPTION ACTIVATION COMPLEX INHIBITORS AND METHODS OF USE THEREOF
US20230135524A1 (en) * 2020-01-21 2023-05-04 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Aryl hydantoin heterocycles and methods of use
CN117120436A (zh) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE69938005T2 (de) 1998-09-22 2009-01-15 Astellas Pharma Inc. Cyanophenyl-derivate
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
WO2003087061A1 (en) 2002-04-12 2003-10-23 Pfizer Japan Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
US20060247286A1 (en) 2003-07-02 2006-11-02 Milton Hammond Oxazolidinone antibiotics and derivatives thereof
US7432378B2 (en) 2003-09-30 2008-10-07 Janssen Pharmaceutica, N.V. Benzoimidazole compounds
EP1706385B1 (en) 2003-12-23 2010-10-06 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
JP4912148B2 (ja) 2004-08-03 2012-04-11 中外製薬株式会社 新規イミダゾリジン誘導体
JP4989227B2 (ja) * 2004-09-09 2012-08-01 中外製薬株式会社 新規イミダゾリジン誘導体およびその用途
DE602005021150D1 (de) 2004-12-03 2010-06-17 Hoffmann La Roche 3-substituierte pyridinderivate als h3-antagonisten
KR101579701B1 (ko) * 2005-05-13 2015-12-22 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
SG170809A1 (en) 2006-03-29 2011-05-30 Univ California Diarylthiohydantoin compounds
JP5535925B2 (ja) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
CL2012000623A1 (es) 2012-09-14
UY32882A (es) 2011-04-29
AR078166A1 (es) 2011-10-19
WO2011029537A1 (en) 2011-03-17
MA33566B1 (fr) 2012-09-01
SG178919A1 (en) 2012-04-27
CU20120042A7 (es) 2012-06-21
MX2012002977A (es) 2012-04-30
TN2012000108A1 (en) 2013-09-19
ECSP12011716A (es) 2012-04-30
AU2010294588A1 (en) 2012-04-05
JP2013504523A (ja) 2013-02-07
CR20120113A (es) 2012-05-02
EP2475653A1 (en) 2012-07-18
CA2773591A1 (en) 2011-03-17
CN102639523A (zh) 2012-08-15
EA201200473A1 (ru) 2012-10-30
IL218390A0 (en) 2012-04-30
KR20120065396A (ko) 2012-06-20
TW201111378A (en) 2011-04-01
NZ598643A (en) 2013-10-25
DOP2012000063A (es) 2012-05-15
US20120251551A1 (en) 2012-10-04
BR112012005526A2 (pt) 2016-04-26
PE20121180A1 (es) 2012-08-24
CO6511228A2 (es) 2012-08-31

Similar Documents

Publication Publication Date Title
IN2012DN02081A (pt)
UA115983C2 (uk) Інгібітори днк-пк
EA020330B3 (ru) Хиназолиновые соединения
MX2011007930A (es) Conjugados de insulina cristalina.
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
MX343706B (es) Derivados heterocíclicos novedosos.
MX356205B (es) Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr).
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
MX352892B (es) Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
MX349004B (es) Nuevos compuestos.
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MX370721B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
MX357502B (es) Derivados de pirrolotriazinona.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX2011013324A (es) Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor.
WO2011084523A3 (en) Ulk1 compositions, inhibitors, screening and methods of use
WO2009151495A3 (en) Oxazole compounds, compositions and methods of use
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
TN2010000463A1 (en) Compositions and methods for preparing and using same
TN2013000327A1 (en) Novel heterocyclic derivatives